MariMed (MRMD) Stock Overview
Engages in cultivation, production, and selling of branded cannabis products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MRMD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
MariMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.087 |
| 52 Week High | US$0.23 |
| 52 Week Low | US$0.067 |
| Beta | 1.12 |
| 1 Month Change | -3.95% |
| 3 Month Change | -18.60% |
| 1 Year Change | -33.31% |
| 3 Year Change | -79.31% |
| 5 Year Change | -89.58% |
| Change since IPO | -78.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.7% | 4.6% | -0.07% |
| 1Y | -33.3% | 29.0% | 13.9% |
Return vs Industry: MRMD underperformed the US Pharmaceuticals industry which returned 29.1% over the past year.
Return vs Market: MRMD underperformed the US Market which returned 13.8% over the past year.
Price Volatility
| MRMD volatility | |
|---|---|
| MRMD Average Weekly Movement | 17.5% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MRMD's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 774 | Jon Levine | www.marimedinc.com |
MariMed Inc. engages in cultivation, production, and selling of branded cannabis products in the United States and internationally. The company sells cannabis flower, vapes, and concentrates under the Nature’s Heritage brand; cannabis fruit chews that delivers better sleep, pain relief, stress relief, and others under Betty’s Eddies brand; and cannabis-infused ice creams under Emack & Bolio's brand. It offers soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; cannabis-infused hydrating drink mix for discrete and on-the-go consumption under Vibations brand; and flower, vapes, and edibles under InHouse brand.
MariMed Inc. Fundamentals Summary
| MRMD fundamental statistics | |
|---|---|
| Market cap | US$34.73m |
| Earnings (TTM) | -US$17.82m |
| Revenue (TTM) | US$157.38m |
Is MRMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRMD income statement (TTM) | |
|---|---|
| Revenue | US$157.38m |
| Cost of Revenue | US$97.09m |
| Gross Profit | US$60.29m |
| Other Expenses | US$78.11m |
| Earnings | -US$17.82m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.045 |
| Gross Margin | 38.31% |
| Net Profit Margin | -11.32% |
| Debt/Equity Ratio | 106.0% |
How did MRMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/08 09:43 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MariMed Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Gomes | NOBLE Capital Markets, Inc. |
| Andrew Semple | Ventum Financial Corp |